ライフサイエンスコーパス: ENT2

1 which ENT expression was limited to ENT1 or ENT2.

2 ty of an alternative nucleoside transporter, ENT2.

3 ide transporter ENT1 and thus was designated ENT2.

4 ate had different IC(50) values for ENT1 and ENT2.

5 ient expression studies with the full-length ENT2 and a 5'-truncated construct that lacks the first s

6 r newly identified crosstalk pathway between ENT2 and alveolar epithelial Adora2b in lung protection

7 Comparison of the ENT2 and HNP36 nucleotide sequences suggested that HNP36

8 y response gene HNP36 is a truncated form of ENT2 and that the full-length open reading frame of ENT2

9 in the equilibrative nucleoside transporter ENT2, and reconstitution of ENT2 into ENT2-deficient cel

10 bits genetic interactions with both ENT1 and ENT2, and that the clathrin adaptors and Sla2p together

11 east endocytic proteins (the epsins Ent1 and Ent2, and the Eps15 homolog Ede1).

12 nhibitors suppressed the expression of ENT1, ENT2, and TK1 and thus decreased (18)F-FLT PET activity.

13 that equilibrative nucleoside transporter 2 (ENT2), but not ENT1, is capable of translocating BAs acr

14 by 30% in ENT1 cells (P = 0.0248) and 27% in ENT2 cells (P = 0.0054).

15 77% in ENT1 cells (P = 0.0463) and by 64% in ENT2 cells (P = 0.0132), which supported computational p

16 orylation of known Akl1 substrates (Sla1 and Ent2) confirmed that Akl1 is hyperactive when not phosph

17 porter ENT2, and reconstitution of ENT2 into ENT2-deficient cells restores 3E10 Fv transport into cel

18 wo redundant genes encoding epsins, ENT1 and ENT2; deleting both genes is lethal.

19 Interestingly, pan1-20 ent2 Delta but not pan1-20 ent1 Delta double mutants had

20 Studies in gene-targeted mice for Ent1 or Ent2 demonstrated selective protection from liver injury

21 ition of Ado transport is in the order ENT3>=ENT2>ENT1, which also corresponds to the intrinsic abili

22 followed by EIDD-1931 (ENT1 IC(50): 259 uM; ENT2 IC(50): 467 uM), whereas molnupiravir was a modest

23 ed [(3)H]uridine uptake (ENT1 IC(50): 39 uM; ENT2 IC(50): 77 uM), followed by EIDD-1931 (ENT1 IC(50):

24 was a modest inhibitor (ENT1 IC(50): 701 uM; ENT2 IC(50): 851 uM).

25 able to interact with the endocytic adaptor Ent2 in a CBM-dependent manner, and HCs encoded by chc1-

26 d protein 9 functional knockouts of ENT1 and ENT2 in HeLa S3 cells were generated and characterized.

27 rved higher expressional levels of ENT1 than ENT2, in conjunction with repression of ENT1 and ENT2 tr

28 ve nucleoside transporters 1 and 2 (ENT1 and ENT2) inhibitory activity albeit less potent than the pr

29 side transporter ENT2, and reconstitution of ENT2 into ENT2-deficient cells restores 3E10 Fv transpor

30 ne) in tissues such as skeletal muscle where ENT2 is predominantly expressed.

31 d that the full-length open reading frame of ENT2 is required for production of a functional plasma m

32 ENT2-mediated BA transport has low affinity, is pH indep

33 xploiting exDNA-driven tumor selectivity and ENT2-mediated nuclear delivery.

34 t1 or Ent2 revealed a selective phenotype in Ent2(-/-) mice, including attenuated pulmonary edema and

35 ereas nevirapine and lexibulin were ENT1 and ENT2 nontransported inhibitors.

36 nslated from a second start codon within the ENT2 open reading frame.

37 singly, the carboxyl-terminal portion of the ENT2 protein was nearly identical to a smaller protein i

38 nt studies in gene-targeted mice for Ent1 or Ent2 revealed a selective phenotype in Ent2(-/-) mice, i

39 g and predicting compounds that are ENT1 and ENT2 substrates and can circumvent the blood-testis barr

40 g and predicting compounds that are ENT1 and ENT2 substrates and can thereby circumvent the BTB throu

41 hree-dimensional pharmacophores for ENT1 and ENT2 substrates and inhibitors and Bayesian machine lear

42 Clofarabine and cladribine were ENT1 and ENT2 substrates, whereas nevirapine and lexibulin were E

43 However, in contrast to ENT1 and ENT2, the endogenous and green fluorescent protein-tagge

44 trated time-dependent repression of ENT1 and ENT2 transcript and protein levels during ALI.

45 , in conjunction with repression of ENT1 and ENT2 transcript and protein levels following warm ischem

46 dual-targeting mechanism based on exDNA and ENT2 transporter expression to enhance nuclear drug deli

47 librative nucleoside transporter (ENT) 1 and ENT2 using Bayesian modeling.

48 FLT is transported into the cell by ENT1 and ENT2, where it is phosphorylated by TK1 and trapped intr

49 the clathrin-binding adaptor proteins Ent1, Ent2, Yap1801, and Yap1802, we identify a second endocyt